Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer

Jennifer Haynes, Trevor D. McKee, Andrew Haller, Yadong Wang, Cherry Leung, Deena M.a. Gendoo, Evelyne Lima‐Fernandes, Antonija Kreso, Robin Wolman, Eva Szentgyörgyi, Douglass Vines, Benjamin Haibe‐Kains, Bradly G. Wouters, Ur Metser, David A. Jaffray, Myles Smith, Catherine O′BrienClinical 2018 · DOI

Abstract

<b>Purpose:</b> Cancer-initiating cells (C-IC) have been described in multiple cancer types, including colorectal cancer. C-ICs are defined by their capacity to self-renew, thereby driving tumor growth. C-ICs were initially thought to be static entities; however, recent studies have determined these cells to be dynamic and influenced by microenvironmental cues such as hypoxia. If hypoxia drives the formation of C-ICs, then therapeutic targeting of hypoxia could represent a novel means to target C-ICs.<b>Experimental Design:</b> Patient-derived colorectal cancer xenografts were treated with evofosfamide, a hypoxia-activated prodrug (HAP), in combination with 5-fluorouracil (5-FU) or chemoradiotherapy (5-FU and radiation; CRT). Treatment groups included both concurrent and sequential dosing regimens. Effects on the colorectal cancer-initiating cell (CC-IC) fraction were assessed by serial passage <i>in vivo</i> limiting dilution assays. FAZA-PET imaging was utilized as a noninvasive method to assess intratumoral hypoxia.<b>Results:</b> Hypoxia was sufficient to drive the formation of CC-ICs and colorectal cancer cells surviving conventional therapy were more hypoxic and C-IC-like. Using a novel approach to combination therapy, we show that sequential treatment with 5-FU or CRT followed by evofosfamide not only inhibits tumor growth of xenografts compared with 5-FU or CRT alone, but also significantly decreases the CC-IC fraction. Furthermore, noninvasive FAZA-PET hypoxia imaging was predictive of a tumor's response to evofosfamide.<b>Conclusions:</b> Our data demonstrate a novel means to target the CC-IC fraction by adding a HAP sequentially after conventional adjuvant therapy, as well as the use of FAZA-PET as a biomarker for hypoxia to identify tumors that will benefit most from this approach. <i>Clin Cancer Res; 24(9); 2116-27. ©2018 AACR</i>.
BibTeX
@inproceedings{haynes2018administration,
  author = {Jennifer Haynes and Trevor D. McKee and Andrew Haller and Yadong Wang and Cherry Leung and Deena M.A. Gendoo and Evelyne Lima‐Fernandes and Antonija Kreso and Robin Wolman and Eva Szentgyörgyi and Douglass Vines and Benjamin Haibe‐Kains and Bradly G. Wouters and Ur Metser and David A. Jaffray and Myles Smith and Catherine O′Brien},
  title = {{Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer}},
  booktitle = {Clinical},
  year = {2018},
  doi = {10.1158/1078-0432.ccr-17-1715},
}

Loading related content...

Figure